The SLP application process is now closed.
Introduction: The Leukemia & Lymphoma Society (LLS) is sponsoring and issuing this Request for Applications (RFA) from qualified academic laboratories for drug discovery support specifically directed towards medicinal chemistry and/or drug target screening in hematological malignancies. LLS recognizes a significant need for investigators to receive resources for high-throughput screening and optimization of small molecules into drug-like compounds suitable for in vivo testing in a disease-relevant model that can be used for further preclinical proof-of-concept testing of the new drug target. Last year, the first year of this new funding mechanism, 6 projects were chosen for funding by an acclaimed peer review panel. This year, 4 new laboratories/projects were selected to participate in this model of collaboration whereby LLS, grantee, sponsoring institution and appropriate contract service organizations (CROs) or core facilities at academic institutions work together to develop compounds with the potential to change the standard of care for patients with blood cancer. Continued funding/sponsorship will be contingent on available funds and assessments of progress toward the goals outlined in each individual proposal accepted by LLS.
Objectives: The goal of this RFA is the development of small molecule for in vivo proof of concept studies in disease relevant animal models for hematological malignancies. Proposals should include strong scientific rationale for a new drug target in a hematological malignancy; provide information to assess existing intellectual property or the potential for novel chemical space; demonstrate or explain how a screening assay can be developed to accommodate a high volume of compounds; or indicate how a tractable lead compound can be further developed.